Atypical neuroleptics in child and adolescent psychiatry

被引:0
作者
Remschmidt, H
Hennighausen, K
Clement, HW
Heiser, P
Schulz, E
机构
[1] Univ Marburg, Dept Child & Adolescent Psychiat, D-35033 Marburg, Germany
[2] Univ Freiburg, Dept Child & Adolescent Psychiat, D-79104 Freiburg, Germany
关键词
atypical neuroleptics; schizophrenia; child; adolescent; psychiatry;
D O I
暂无
中图分类号
B844 [发展心理学(人类心理学)];
学科分类号
040202 ;
摘要
Atypical neuroleptics have enriched our treatment programmes, especially in childhood and adolescent schizophrenia. This article reviews the use of atypical neuroleptics in children and adolescents with schizophrenic disorder. It considers the receptor binding profile and pharmacological properties, indications, side effects, clinical applications and trials of atypical neuroleptics in comparison to the classical neuroleptic haloperidol in adolescent schizophrenia. Special emphasis is placed on the most common atypical neuroleptics clozapine, olanzapine and risperidone since most studies are carried out with these compounds, especially with clozapine. More clinically controlled trials have to be conducted since only one was performed so far. The place of the atypical neuroleptics is discussed and further studies are necessary in order to differentiate the indications tested so far and to find out if the spectrum of indications can be broadened.
引用
收藏
页码:9 / 19
页数:11
相关论文
共 55 条
[1]  
Abczynska M, 1995, Psychiatr Pol, V29, P79
[2]   Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: Simultaneous determination by a high performance liquid chromatography with electrochemical detection [J].
Aravagiri, M ;
Marder, SR ;
Wirshing, D ;
Wirshing, WC .
PHARMACOPSYCHIATRY, 1998, 31 (03) :102-109
[3]   Risperidone in adolescents with schizophrenia: An open pilot study [J].
Armenteros, JL ;
Whitaker, AH ;
Welikson, M ;
Stedge, DJ ;
Gorman, J .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1997, 36 (05) :694-700
[4]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[5]   CLOZAPINE FOR SCHIZOPHRENIA [J].
BLANZ, B ;
SCHMIDT, MH .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1993, 32 (01) :223-224
[6]  
BLEEHAM T, 1993, LEPONEX R CLOZARIL R
[7]   Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study [J].
Bondolfi, G ;
Dufour, H ;
Patris, M ;
May, JP ;
Billeter, U ;
Eap, CB ;
Baumann, P .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (04) :499-504
[8]   RISPERIDONE - REVIEW AND ASSESSMENT OF ITS ROLE IN THE TREATMENT OF SCHIZOPHRENIA [J].
CARDONI, AA .
ANNALS OF PHARMACOTHERAPY, 1995, 29 (06) :610-618
[9]   RISPERIDONE IN THE TREATMENT OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA - A METAANALYSIS [J].
CARMAN, J ;
PEUSKENS, J ;
VANGENEUGDEN, A .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 (04) :207-213
[10]  
CASEY DE, 1989, PSYCHOPHARMACOLOGY, V99, P47